| Income Statement | 2025-04-30 | |||
|---|---|---|---|---|
| Revenues | 6,402 | |||
| Selling, general and administrative | 4,904 | |||
| Research and development | 504 | |||
| Legal and related expense, net | 465 | |||
| Cost of revenues | 3,755 | |||
| Cost of revenues inventory provision | 163 | |||
| Total operating costs and expenses | 9,791 | |||
| Operating loss | -3,389 | |||
| Other | 123 | |||
| Interest, net | 384 | |||
| Foreign exchange (loss) gain | 508 | |||
| Total other income (expense), net | 1,015 | |||
| Loss before income taxes | -2,374 | |||
| Net loss from continuing operations | -2,374 | |||
| Net loss from discontinued operations | -416 | |||
| Net loss | -2,790 | |||
| Total net loss per basic and diluted common share (in dollars per share) | -0.05 | |||
| Total net loss per diluted common share (in dollars per share) | -0.05 | |||
| Basic (in shares) | 52,403 | |||
| Diluted (in shares) | 52,403 | |||
ENZO BIOCHEM INC (ENZB)
ENZO BIOCHEM INC (ENZB)